ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS
https://doi.org/10.20996/1819-6446-2010-6-1-84-88
Abstract
The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors give special attention to new alternative drugs for prevention of thrombotic complications apart from old known antiplatelet drugs.
About the Authors
M. Yu. Gilyarov
Moscow Medical Academy named after M.I. Setchenov
Russian Federation
Russian Federation
Chair of preventive and emergency cardiology
Bolshaya Pirogovskaya ul 6, Moscow 119992
V. A. Sulimov
Moscow Medical Academy named after M.I. Setchenov
Russian Federation
Russian Federation
Chair of preventive and emergency cardiology
Bolshaya Pirogovskaya ul 6, Moscow 119992
References
1. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of theAmerican College of Cardiology/AmericanHeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.
2. Scholten M.F., Thornton A.S., Mekel J.M. et al. Anticoagulation in atrial fibrillation and flutter. Europace 2005;7(5):492-9.
3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449-57.
4. Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35(1):183-7.
5. Hohnloser S.H., Pajitnev D., Pogue J. et al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy:AnACTIVEWSubstudy.JAmCollCardiol2007;50(22):2156-61.
6. Nieuwlaat R., Dinh T., Olsson S.B. et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29(7):915-22.
7. Fang M.C., Go A.S., Chang Y. et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51(8):810-5.
8. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501.
9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67.
10. Fuster V., Ryden L. E., Asinger R. W. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee toDevelop Guidelines forthe Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38(4):1231-66.
11. Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):546S-592S.
12. Панченко Е.П., Кропачева Е.С. Профилактика тромбоэмболий у больных мерцательной аритмией. М.: МИА; 2007.
13. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dosewith clinical and pharmacogenetic data. N EnglJMed2009;360(8):753- 64.
14. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 2009;360(20):2066-78.
15. The ACTIVE Writing Group Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903-12.
16. Albers GW; SPORTIF Investigators. Stroke Prevention in Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Trials. Am J Manag Care 2004;10(14 Suppl):S462- 9.
17. Стуров Н.В., Моисеев В.С. Клиническая фармакология дабигатрана, представителя нового класса антикоагулянтов — прямых ингибиторов тромбина. Клиническая фармакология и терапия 2009;(5):32-7.
18. Blech S., Ebner T., Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36(2):386-99.
19. Mismetti P, Laporte S.Dabigatran: clinical pharmacology (in French).Ann FrAnesth Reanim 2009;28(9 Suppl):S8-14.
20. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.
21. Ezekowitz M.D., Connolly S., Parekh A. et al. Rationale and design of RE-LY: randomized evaluation oflong-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157(5):805-10.
22. Wallentin L. RE-LY: Post Hoc Analysis Confirms Benefit of Dabigatran Relative to Warfarin at All INR Levels. AmericanHeart Association (AHA) 2009 Scientific Sessions: Abstract 101. Presented November 15, 2009; Orlando. Available at http://www.medscape.com/viewarticle/712556.
Review
For citations:
Gilyarov M.Yu., Sulimov V.A. ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS. Rational Pharmacotherapy in Cardiology. 2010;6(1):84-88. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-84-88
Views:
626
Email this article 